CA
SYRS

Centerpoint Advisors’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Centerpoint Advisors’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,659
Closed -$2K – 480
2024
Q4 		$2K Hold
10,659
– – ﹤0.01% 418
2024
Q3 		$23K Buy
+10,659
New +$38.3K 0.01% 253

Other funds holding SYRS

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Centerpoint Advisors's SYRS Position: Q1 2025 in Review

Centerpoint Advisors sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 10,659 shares — an estimated $2K sold.

Centerpoint Advisors first reported a position in SYRS in Q3 2024 and held it in 2 quarters. The position peaked at $23K in Q3 2024. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.

  • Centerpoint Advisors reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Centerpoint Advisors sold 10,659 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $2K.
  • Centerpoint Advisors first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2024 and held it in 2 quarters.
  • Centerpoint Advisors's Syros Pharmaceuticals, Inc. Common Stock position peaked at $23K in Q3 2024.
  • 7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.

Based on Centerpoint Advisors's 13F filing for Q1 2025, filed 13 May 2025.